Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Q1 2025 Earnings Presentation
17 slides from Zealand Pharma A/s's earnings presentation, May 8, 2025
Slide 1: Q1 2025 Presentation
Q1 2025 Presentation Zealand Pharma May 8, 2025 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda Q&A Opening remarks R&D pipeline Financials Adam Steensberg David Kendall Henriette Wennicke Chief Executive Chief Medical Chief Financial Officer Officer Officer 3
Slide 4: Zealand Pharma has never been in a stronger position
Zealand Pharma has never been in a stronger position as we strive to become a key player in obesity Differentiated mid- to late-stage obesity pipeline (petrelintidea, petrelintide/CT-388a, dapiglutide, survodutideb) Progressing rare disease programs with clear path forward (dasiglucagon for CHI, gle
Slide 5: Significant strengthening of organization to build the foundation for the next phase of growth
Significant strengthening of organization to build the foundation for the next phase of growth Building capabilities to enable Key senior hires in 2025 continued growth journey Research Invest significantly in early-stage Utpal Singh (Chief Scientific Officer) research pipeline targeting obesity and
Slide 6: The obesity pandemic represents one of the greatest healthcare challenges of our time
The obesity pandemic represents one of the greatest healthcare challenges of our time Early days in the evolution of this market… For 300,000 years, human beings maintained a relatively stable BMI… Eligible patients in the US receiving ~2% prescriptions for weight loss therapy2 The obesity pandemic
Slide 7: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Petrelintide (amylin analog)b Obesity related co-morbidities Petrelintide/CT-388 (amylin + GLP-1/GIP)b Obesity Obesity and Dapiglutide (GLP
Slide 8: Zealand Pharma and Roche aim to establish the leading amylin-based weight management franchise
Obesity Petrelintide Zealand Pharma and Roche aim to establish the leading amylin-based weight management franchisea Developing petrelintide as a future foundational therapy for weight management with the ambition to rapidly expand into obesity-related comorbidities Key unmet medical needs Current c
Slide 9: Developing petrelintide as monotherapy through large, comprehensive Phase 2 program (ZUPREME)
Obesity Petrelintide Developing petrelintide as monotherapy through large, comprehensive Phase 2 program (ZUPREME) The Phase 2 ZUPREME program will guide design of Phase 3 trials ZUPREME-1: Overweight/obesity without T2D1 ZUPREME-2: Overweight/obesity with T2D2 Initiated in December 2024 Initiated i
Slide 10: Truly differentiated GLP-1RA-based therapies targeting obesity and related comorbidities
Obesity Survodutide Dapiglutide Truly differentiated GLP-1RA-based therapies targeting obesity and related comorbidities Survodutide (GCG/GLP-1): Potential first- and Dapiglutide (GLP-1/GLP-2): Potential first-in-class best-in-class targeting obesity and MASH targeting obesity and low-grade inflamma
Slide 11: We remain committed to bringing our rare disease programs to patients as soon as possible
Rare diseases We remain committed to bringing our rare disease programs to patients as soon as possible Dasiglucagona: Congenital hyperinsulinism Glepaglutideb: Short bowel syndrome Timing of next steps contingent on third-party Type A meeting with the U.S. FDA completed, manufacturing facility rece
Slide 12: Q1 2025 Profit & Loss
Financials Q1 2025 Profit & Loss P&L reflecting Zealand’s investments in its DKK million Q1 2025 Q1 2024 differentiated R&D assets and organization Revenue 8.1 15.1 • Revenue of DKK 8 million is mainly driven by the license and Gross profit 7.7 10.5 development agreement with Novo Nordisk for Zegalo
Slide 13: Well-funded with no need to raise additional capital towards expected profitability
Financials Well-funded with no need to raise additional capital towards expected profitability Solid financial position with ample room for investments in the R&D pipeline DKK million ~17,744 Other near-term payments include 250 mUSD in Honor cost obligations under anniversary payments over two year
Slide 14: 2025 financial guidance
Financials 2025 financial guidance DKK million 2025 2024 Guidancea Actuals Revenue anticipated from existing and new license and No guidance 63 partnership agreements Net operating expensesb 2,000 – 2,500 1,327 aFinancial guidance on net operating expenses for 2025, published on February 20, 2025, i
Slide 15: Exciting news flow with many potential catalysts in the next ~12 months
Exciting news flow with many potential catalysts in the next ~12 months NON-EXHAUSTIVE Q2 2025 H2 2025 H1 2026 Petrelintidea Survodutideb Petrelintidea Subgroup analysis from Part 2 of Ph1b trial Completion of Ph3 obesity trials Topline results from Ph2 ZUPREME-1 trial (16wks) at ADA 2025 (SYNCHRONI
Slide 16: Zealand Pharma Capital Markets Day December 11, 2025
Zealand Pharma Capital Markets Day December 11, 2025 SAVE THE DATE: December 11, 2025 Location: London (virtual attendance possible) Speakers will include Zealand Pharma Management as well as external experts and thought leaders in obesity More information to follow 16
Slide 17: Zealand Pharma upcoming investor events
Q&A Zealand Pharma upcoming investor events • Bank of America Healthcare Conference, Las Vegas, May 13-14 • Berenberg 11th European Conference, New York, May 20 • Barclays European Leadership Conference, London, May 22 • Jefferies Global Healthcare Conference, New York, June 4-5 • Goldman Sachs 46th